Awards
- Honorary Professor of Surgery, University of Larissa, Greece, 2023
- Board Member International Centre of Excellence for Technical Innovation in Surgery, University of Naples, Itlay, 2017
- Honorary Foreign Member, French Academy of Surgery, 2015
- Honorary Diploma, Bulgarian Surgical Society, 2014
- Scientific and Technological Achievement, TAKREEM, 2012
- Named as one of top 100 surgeons in the UK, The Times newspaper, 2011
- Doctor Honoris Causa, University of Medicine and Pharmacy, Cluj-Napoca, Romania, 2011
- Gold Clinical Excellence Award, ACCEA, 2011
- Visiting Professor of Hepatic Surgery, First Affiliated Hospital of Harbin Medical University, 2010
- Visiting Professor of Hepatobiliary Department, Tainjian Medical Univeristy Cancer Institute, 2010
External Positions
- Peer Reviewer, PhD Committee, Univeristy of Messina, Department of Pathology, Italy, 2010
- Board Member, International Association of Surgeons and Gastroenterologists, 2005
- President, Past President and Board Member, International Society of Cell & Gene Therapy of Cancer, 2003 - 2017
Membership of Professional Bodies
- Full Member, American Association for Cancer Research, 2017
- Full Member, London Regenerative Medicine Network, 2017
- Full Member, European Surgical Association, 2010
- Full Member and Past President, International Society of Cell and Gene Therapy for Cancer, 2004
- Full Member, Oligonucleotide Therapeutics Society, 2002
- Full Member, American Society for Gene and Cell Therapy, 2000
- Full Member, American Association for study of the Liver Diseases, 2000
- Full Member, American Association of Clinical Oncology, 2000
- Full Member, International Hepato-Pancreato-Biliary Association, 2000
Links with Other Academic Bodies
- A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), The National Cancer Centre Singapore, 2016
- A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), Cambridge University Hospitals NHS Trust, 2016
- A First-in-Human, multi-centre, open-label, phase 1 clinical study with RNA oligonucleotide drug MTL-CEBPA to investigate its safety and tolerability in patients with advanced liver cancer (OUTREACH)., Guys & St Thomas Foundation TrustKings College University, 2016
- A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), National Taiwan University Hospital, 2016
- Department of Research Oncology, King’s College London, 3rd Floor, Bermondsey Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT, United Kingdom, The Beatson West of Scotland Cancer CentreCancer Research UK Clinical Trials Unit, 1053 Great Western Rd, Glasgow G12 0YN, United Kingdom, 2016
- A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), The Clatterbridge Cancer Centre NHS Foundation Trust, 2016
- A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), University College London Hospitals NHS Foundation Trust, 2016
- A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), University Hospitals Birmingham NHS Foundation Trust, 2016
- Development and innovation in endoscopic medical devices, Weill Cornell Medicine, 2014
- Development and targeting of aptamers in liver diseases., Professor John Rossi, Beckman Research Institute, City of Hope, 2013
- A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH), The Newcastle upon Tyne Hospitals NHS Foundation Trust
Industrial Connections
- Apterna Limited, Director
- EMcision Limited, Board Member, Director
- MiNA Therapeutics Ltd, Cheif Medical Officer for clinical study:A FIRST-IN-HUMAN, MULTI-CENTRE, OPEN-LABEL, PHASE 1 CLINICAL STUDY WITH RNA OLIGONUCLEOTIDE DRUG MTL-CEBPA TO INVESTIGATE ITS SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED LIVER CANCER (OUTREACH) Study
- OmniCyte Limited, Director
Commercial Spinoffs
- EMcision Limited
- OmniCyte Limited and Associated Companies, Board Member, Regenerative medicine in the field of stem cells, 2003
Fellowships
- Fellow, Royal College of Surgeons of Edinburgh
Editorial Boards
- World Journal of Gastroenterology, Editorial Board
- Molecular Therapeutics Nucleic Acids (Open Access journal), Deputy Editor
- Hepatoma, Deputy Chief Editor, 2012 - 2015
- Clinical Oncology and Cancer Research, Editorial Board, 2012
- Cancer Biology and Therapy, Editorial Board Member, 2001
- Cancer Gene Therapy Journal, Editorial Board Member, 1999
- Chirurgie, Editorial Board Member, 1998